Imatinib Increases Serum Creatinine by Inhibiting Its Tubular Secretion in a Reversible Fashion in Chronic Myeloid Leukemia.
about
Targeting the tyrosine kinase signalling pathways for treatment of immune-mediated glomerulonephritis: from bench to bedside and beyond.Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease.Beyond drug-drug interactions: effects of transporter inhibition on endobiotics, nutrients and toxins.Changes from imatinib mesylate to second generation tyrosine kinase inhibitors improve renal impairment with imatinib mesylate in chronic myelogenous leukemia.Effect of tyrosine kinase inhibitors on renal handling of creatinine by MATE1.
P2860
Imatinib Increases Serum Creatinine by Inhibiting Its Tubular Secretion in a Reversible Fashion in Chronic Myeloid Leukemia.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Imatinib Increases Serum Creat ...... n in Chronic Myeloid Leukemia.
@en
type
label
Imatinib Increases Serum Creat ...... n in Chronic Myeloid Leukemia.
@en
prefLabel
Imatinib Increases Serum Creat ...... n in Chronic Myeloid Leukemia.
@en
P2093
P1476
Imatinib Increases Serum Creat ...... n in Chronic Myeloid Leukemia.
@en
P2093
Claude Gardin
Fidéline Serrano
Marie-Noëlle Peraldi
Martin Flamant
Philippe Rousselot
Thomas Stehlé
P304
P356
10.1016/J.CLML.2015.12.001
P407
P577
2015-12-20T00:00:00Z